Immunological mechanisms behind the cystic

Medical Mycology

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Hartl, Dominik ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Allergic bronchopulmonary aspergillosis (ABPA); Aspergillus; CCL17; CCL22; CCR4; Chemokine receptors; Chemokines; Cystic fibrosis (CF); TARC; Th2

Indexed keywords

CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CXCR3; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; MACROPHAGE DERIVED CHEMOKINE; RANTES; T LYMPHOCYTE RECEPTOR; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR NFAT; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ALLERGIC ASTHMA; ARTICLE; ASPERGILLUS FUMIGATUS; BRONCHOPULMONARY ASPERGILLOMA; CD4+ T LYMPHOCYTE; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; NATURAL KILLER T CELL; NONHUMAN; PATHOPHYSIOLOGY; REGULATORY T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ANIMALIA; ASPERGILLUS; ASPERGILLUS FUMIGATUS;

EID: 68449101095     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802189938     Document Type: Article

References (120)

1. Cockrill BA, Hales CA. Allergic bronchopulmonary aspergillosis. Annu Rev Med 1999; 50: 303-316.
2. Nelson LA, Callerame ML, Schwartz RH. Aspergillosis and atopy in cystic fibrosis. Am Rev Respirat Dis 1979; 120: 863-873.
3. Moss RB. Pathophysiology and immunology of allergic bronchopulmonary aspergillosis. Med Mycol 2005; 43 (Suppl. 1):S203-206.
4. Geller DE, Kaplowitz H, Light MJ, Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: Reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Chest 1999; 116: 639-646.
5. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110: 685-692.
6. Moss RB. Allergic bronchopulmonary aspergillosis. Clin Rev Allergy Immunol 2002; 23: 87-104.x
7. Paul KD, Leupold W, BlaschkeHellmessen R, et al. Allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis (CF). Clinical importance, diagnosis and treatment. Mycoses 1996; 39: 55-58.
8. Becker JW, Burke W, McDonald G, et al. Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis. Chest 1996; 109: 1536-1540.
9. Knutsen AP, Mueller KR, Hutcheson PS, Slavin RG. Serum anti- Aspergillus fumigatus antibodies by immunoblot and Elisa in cystic fibrosis with allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1994; 93: 926-931.
10. Skov M, Koch C, Reimert CM, Poulsen LK. Diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis. Allergy 2000; 55: 50-58.
11. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis - state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37: S225-264.
12. Schwartz RH, Hollick GE. Allergic bronchopulmonary aspergillosis (ABPA) with low serum Ige. Pediatric Res 1981; 15: 603.
13. Takhar P, Corrigan CJ, Smurthwaite L, et al. Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol 2007; 119: 213-218.
14. Kurup VP, Choi H, Murali PS, Coffman RL. IgE and eosinophil regulation in a murine model of allergic aspergillosis. J Leukoc Biol 1994; 56: 593-598.
15. Kurup VP, Seymour BW, Choi H, Coffman RL. Particulate Aspergillus fumigatus antigens elicit a TH2 response in BALB/c mice. J Allergy Clin Immunol 1994; 93: 1013-1020.
16. Chauhan B, Knutsen AP, Hutcheson PS, Slavin RG, Bellone CJ. T cell subsets, epitope mapping, and HLA-restriction in patients with allergic bronchopulmonary aspergillosis. J Clin Investigat 1996; 97: 2324-2331.
17. Knutsen AP, Mueller KR, Marino N, Hutcheson PS, Slavin RG. Immune changes in allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) subjects. J Allergy Clin Immunol 1989; 83: 183.
18. Knutsen AP. Lymphocytes in allergic bronchopulmonary aspergillosis. Frontiers Biosci 2003; 8: D589-602.
19. Rathore VB, Johnson B, Fink JN, et al. T cell proliferation and cytokine secretion to T cell epitopes of Asp f 2 in ABPA patients. Clin Immunol 2001; 100: 228-235.
20. Knutsen AP, Mueller KR, Levine AD, et al. Asp f I CD4+TH2-like T-cell lines in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1994; 94 (2 Pt 1): 215-221.
21. McClellan JS, Roodman ST, Chauhan B, et al. Increased sensitivity to IL-4 in patients with allergic bronchopulmonary aspergillosis (ABPA). J Allergy Clin Immunol 1999; 103: S16.
22. Khan S, McClellan JS, Knutsen AP. Increased sensitivity to IL-4 in patients with allergic bronchopulmonary aspergillosis. Int Arch Allergy Immunol 2000; 123: 319-326.
23. Walker C, Bauer W, Braun RK, et al. Activated T-cells and cytokines in bronchoalveolar lavages from patients with various lung-diseases associated with eosinophilia. Am J Respirat Crit Care Med 1994; 150: 1038-1048.
24. Casaulta C, Schoni MH, Weichel M, et al. IL-10 controls Aspergillus fumigatus- and Pseudomonas aeruginosa-specific Tcell response in cystic fibrosis. Pediatr Res 2003; 53: 313-319.
25. Grunig G, Corry DB, Leach MW, et al. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J Exp Med 1997; 185 1089-1099.
26. Roilides E, Dimitriadou A, Kadiltsoglou I, et al. IL-10 exerts suppressive and enhancing effects on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Immunol 1997; 158: 322-329.
27. Knutsen AP, Slavin RG. Immune dysfunction in cystic fibrosis (CF) patients with Allergic bronchopulmonary aspergillosis (ABPA). J Allergy Clin Immunol 1987; 79: 143.
28. Allard JB, Poynter ME, Marr KA. Aspergillus fumigatus generates an enhanced Th2-biased immune response in mice with defective cystic fibrosis transmembrane conductance regulator. J Immunol 2006; 177: 5186-5194.
29. Moss RB, Hsu YP, Olds L. Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clin Exp Immunol 2000; 120: 518-525.
30. Kelley TJ, Drumm ML. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 1998; 102: 1200-1207.
31. Kelley TJ, Elmer HL. In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium. J Clin Invest 2000; 106: 403-410.
32. Steagall WK, Elmer HL, Brady KG, Kelley TJ. Cystic fibrosis transmembrane conductance regulator-dependent regulation of epithelial inducible nitric oxide synthase expression. Am J Respir Cell Mol Biol 2000; 22: 45-50.
33. Hartl D, Griese M, Kappler M, et al. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006; 117: 204-211.
34. Kraemer R, Delosea N, Ballinari P, Gallati S, Crameri R. Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2006; 174: 1211-1220.
35. Boucher RC. Airway surface dehydration in cystic fibrosis: Pathogenesis and therapy. Annu Rev Med 2007; 58: 157-170.
36. Dubin PJ, McAllister F, Kolls JK. Is cystic fibrosis a TH17 disease? Inflamm Res 2007; 56: 221-227.
37. Chauhan B, Santiago L, Kirschmann DA, et al. The association of HLA-DR alleles and T cell activation with allergic bronchopulmonary aspergillosis. J Immunol 1997; 159: 4072-4076.
38. Knutsen AP, Kariuki B, Consolino JD, Warrier MR. IL-4 alpha chain receptor (IL-4Ralpha) polymorphisms in allergic bronchopulmonary sspergillosis. Clin Mol Allergy 2006; 4: 3.
39. Brouard J, Knauer N, Boelle PY, et al. Influence of interleukin- 10 on Aspergillus fumigatus infection in patients with cystic fibrosis. J Infect Dis 2005; 191: 1988-1991.
40. Saxena S, Madan T, Shah A, Muralidhar K, Sarma PU. Association of polymorphisms in the collagen region of SP-A2 with increased levels of total IgE antibodies and eosinophilia in patients with allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2003; 111: 1001-1007.
41. Wojnarowski C, Eichler I, Gartner C, Gotz M, Renner S, Koller DY, et al. Sensitization to Aspergillus fumigatus and lung function in children with cystic fibrosis. Am J Respir Crit Care Med 1997; 155: 1902-1907.
42. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-445.
43. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001; 2: 123-128.
44. Moser B, Willimann K. Chemokines: Role in inflammation and immune surveillance. Ann Rheum Dis 2004; 63 (Suppl. 2): Ii84-89.
45. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998; 19: 568-574.
46. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997; 277: 2005-2007.
47. D'Ambrosio D, Iellem A, Bonecchi R, et al. Selective upregulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol 1998; 161: 5111-5115.
48. Miyazaki E, Nureki S, Fukami T, et al. Elevated levels of thymus- and activation-regulated chemokine in bronchoalveolar lavage fluid from patients with eosinophilic pneumonia. Am J Respir Crit Care Med 2002; 165: 1125-1131.
49. Holgate ST, Bodey KS, Janezic A, et al. Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am J Respir Crit Care Med 1997; 156: 1377-1383.
50. Holgate ST. Asthma: A dynamic disease of inflammation and repair. Ciba Found Symp 1997; 206: 5-28.
51. Holgate ST. Airway inflammation and remodeling in asthma: Current concepts. Mol Biotechnol 2002; 22: 179-189.
52. Hartl D, Griese M, Nicolai T, et al. Pulmonary chemokines and their receptors differentiate children with asthma and chronic cough. J Allergy Clin Immunol 2005; 115: 728-736.
53. Berin MC. The role of TARC in the pathogenesis of allergic asthma. Drug News Perspect 2002; 15: 10-16.
54. Shimada Y, Takehara K, Sato S. Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. J Dermatological Sci 2004; 34: 201-208.
55. Morita E, Hiragun T, Mihara S, et al. Determination of thymus and activation-regulated chemokine (TARC)-contents in scales of atopic dermatitis. J Dermatological Sci 2004; 34: 237-240.
56. Leung TF, Ma KC, Hon KL, et al. Serum concentration of macrophage-derived chemokine may be a useful inflammatory marker for assessing severity of atopic dermatitis in infants and young children. Pediat Allergy Immunol 2003; 14: 296-301.
57. Pardo A, Smith KM, Abrams J, et al. CCL18/DC-CK-1/PARC up-regulation in hypersensitivity pneumonitis. J Leukocyte Biol 2001; 70: 610-616.
58. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2 108-115.
59. Hijnen DJ, Bruin-Weller M, Oosting B, et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cellattracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004; 113: 334-340.
60. Hirata H, Arima M, Cheng G, et al. Production of TARC and MDC by naive T cells in asthmatic patients. J Clin Immunol 2003; 23 34-45.
61. Hartl D, Griese M, Nicolai T, et al. Pulmonary chemokines and their receptors differentiate children with asthma and chronic cough. J Allergy Clin Immunol 2005; 115: 728-736.
62. Hartl D, Latzin P, Zissel G, et al. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med 2006; 173: 1370-1376.
63. Kakinuma T, Nakamura K, Wakugawa M, et al. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001; 107: 535-541.
64. Kakinuma T, Nakamura K, Wakugawa M, et al. Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis. Clin Experim Immunol 2002; 127: 270-273.
65. Latzin P, Hartl D, Regamey N, et al. Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J 2008; 1: 36-42.
66. Leung TF, Wong CK, Lam CW, et al. Plasma TARC concentration may be a useful marker for asthmatic exacerbation in children. Eur Respir J 2003; 21: 616-620.
67. Leung TF, Wong CK, Chan IHS, et al. Plasma concentration of thymus and activation-regulated chemokine is elevated in childhood asthma. J Allergy Clin Immunol 2002; 110: 404-409.
68. Pilette C, Francis JN, Till SJ, et al. CCR4 ligands are upregulated in the airways of atopic asthmatics after segmental allergen challenge. Eur Respir J 2004; 23: 876-884.
69. Sekiya T, Yamada H, Yamaguchi M, et al. Increased levels of a TH2-type CC chemokine thymus and activation-regulated chemokine (TARC) in serum and induced sputum of asthmatics. Allergy 2002; 57: 173-177.
70. Campbell JJ, Brightling CE, Symon FA, et al. Expression of chemokine receptors by lung T cells from normal and asthmatic subjects. J Immunol 2001; 166: 2842-2848.
71. Durham S, Nouri-Aria KT, Wilson DR, et al. Regulation of CCR4 expression after segmental bronchial allergen challenge in atopic asthmatics. J Allergy Clin Immunol 2002; 109: S41.
72. Kurashima K, Fujimura M, Myou S, et al. Asthma severity is associated with an increase in both blood CXCR3+ and CCR4+ T cells. Respirology 2006; 11: 152-157.
73. Nouri-Aria KT, Wilson D, Francis JN, et al. CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol 2002; 32: 1933-1938.
74. Schuh JM, Blease K, Kunkel SL, et al. Airway hyperresponsiveness, but not airway remodeling, is attenuated during chronic pulmonary allergic responses to aspergillus in CCR4-/-mice. Faseb J 2002; 16: A331.
75. Conroy DM, Jopling LA, Lloyd CM, et al. CCR4 blockade does not inhibit allergic airways inflammation. J Leukoc Biol 2003; 74 558-563.
76. Chvatchko Y, Hoogewerf AJ, Meyer A, et al. A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock. J Exp Med 2000; 191: 1755-1764.
77. Kawasaki S, Takizawa H, Yoneyama H, et al. Intervention of thymus and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsiveness in mice. J Immunol 2001; 166: 2055-2062.
78. Bernardini G, Hedrick J, Sozzani S, et al. Identification of the CC chemokines TARC and macrophage inflammatory protein-1 beta as novel functional ligands for the CCR8 receptor. Eur J Immunol 1998; 28: 582-588.
79. Gutierrez-Ramos JC, Lloyd C, Kapsenberg ML, et al. Nonredundant functional groups of chemokines operate in a coordinate manner during the inflammatory response in the lung. Immunol Rev 2000; 177 31-42.
80. Lloyd CM, Delaney T, Nguyen T, et al. CC chemokine receptor (CCR 3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J Exp Med 2000; 191: 265-274.
81. Gonzalo JA, Pan Y, Lloyd CM, et al. Mouse monocyte-derived chemokine is involved in airway hyperreactivity and lung inflammation. J Immunol 1999; 163: 403-411.
82. Chensue SW, Lukacs NW, Yang TY, et al. Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. J Exp Med 2001; 193: 573-584.
83. Chung CD, Kuo F, Kumer J, et al. CCR8 is not essential for the development of inflammation in a mouse model of allergic airway disease. J Immunol 2003; 170: 581-587.
84. Goya I, Villares R, Zaballos A, et al. Absence of CCR8 does not impair the response to ovalbumin-induced allergic airway disease. J Immunol 2003; 170: 2138-2146.
85. Campbell JJ, Pan J, Butcher EC. Cutting edge: Developmental switches in chemokine responses during T cell maturation. J Immunol 1999; 163: 2353-2357.
86. Lee I, Wang L, Wells AD, et al. Recruitment of Foxp3-T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 2005; 201: 1037-1044.
87. Hartl D, Buckland KF, Hogaboam CM. Chemokines in allergic aspergillosis - from animal models to human lung diseases. Inflamm Allergy Drug Targets 2006; 5: 219-228.
88. Kurup VP, Raju R, Manickam P. Profile of gene expression in a murine model of allergic bronchopulmonary aspergillosis. Infect Immun 2005; 73: 4381-4384.
89. Hogaboam CM, Blease K, Mehrad B, et al. Chronic airway hyperreactivity, goblet cell hyperplasia, and peribronchial fibrosis during allergic airway disease induced by Aspergillus fumigatus. Am J Pathol 2000; 156: 723-732.
90. Galimberti D, Scalabrini D, Fenoglio C, et al. Gender-specific influence of the chromosome 16 chemokine gene cluster on the susceptibility to Multiple Sclerosis. J Neurol Sci 2008; 267 86-90.
91. Netea MG, Van der GC, Van der Meer JW, Kullberg BJ. Recognition of fungal pathogens by Toll-like receptors. Eur J Clin Microbiol Infect Dis 2004; 23: 672-676.
92. Roeder A, Kirschning CJ, Rupec RA, et al. Toll-like receptors as key mediators in innate antifungal immunity. Med Mycol 2004; 42 485-498.
93. Bellocchio S, Montagnoli C, Bozza S, et al. The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol 2004; 172: 3059-3069.
94. Mambula SS, Sau K, Henneke P, et al. Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem 2002; 277: 39320-39326.
95. Blease K, Kunkel SL, Hogaboam CM. IL-18 modulates chronic fungal asthma in a murine model; putative involvement of Tolllike receptor-2. Inflamm Res 2001; 50: 552-560.
96. Braedel S, Radsak M, Einsele H, et al. Aspergillus fumigatus antigens activate innate immune cells via toll-like receptors 2 and 4. Br J Haematol 2004; 125: 392-399.
97. Meier A, Kirschning CJ, Nikolaus T, et al. Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activation of murine macrophages. Cell Microbiol 2003; 5: 561-570.
98. Borger P, Koeter GH, Timmerman JA, et al. Proteases from Aspergillus fumigatus induce interleukin (IL)-6 and IL-8 production in airway epithelial cell lines by transcriptional mechanisms. J Infect Dis 1999; 180: 1267-1274.
99. DeHart DJ, Agwu DE, Julian NC, Washburn RG. Binding and germination of Aspergillus fumigatus conidia on cultured A549 pneumocytes. J Infect Dis 1997; 175: 146-150.
100. Bozza S, Gaziano R, Spreca A, et al. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. J Immunol 2002; 168: 1362-1371.
101. Matsukawa A, Lukacs NW, Hogaboam CM, Chensue SW, Kunkel SL. III. Chemokines and other mediators, 8. Chemokines and their receptors in cell-mediated immune responses in the lung. Microscopy Res Technique 2001; 53: 298-306.
102. Vulcano M, Albanesi C, Stoppacciaro A, et al. Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur J Immunol 2001; 31: 812-822.
103. Montagnoli C, Bozza S, Gaziano R, et al. Immunity and tolerance to Aspergillus fumigatus. Novartis Found Symp 2006; 279: 66-77.
104. Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 2006; 108: 2265-2274.
105. Panina-Bordignon P, Papi A, Mariani M, et al. The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Investigat 2001; 107: 1357-1364.
106. Montagnoli C, Fallarino F, Gaziano R, et al. Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. J Immunol 2006; 176: 1712-1723.
107. Jakubzick C,Wen H,Matsukawa A, et al. Role of CCR4 ligands, CCL17 and CCL22, during Schistosoma mansoni egg-induced pulmonary granuloma formation in mice. Am J Pathol 2004; 165: 1211-1221.
108. Hogaboam CM, Blease K, Schuh JM. Cytokines and chemokines in allergic bronchopulmonary aspergillosis (ABPA) and experimental Aspergillus induced allergic airway or asthmatic disease. Frontiers Biosci 2003; 8: E147-156.
109. Steele C, Rapaka RR, Metz A, et al. The beta-glucan receptor dectin-1 recognizes specific morphologies of Aspergillus fumigatus PLoS Pathog 2005; 1: E42.
110. Hohl TM, Van Epps HL, Rivera A, et al. Aspergillus fumigatus triggers inflammatory responses by stage-specific beta-glucan display. PLoS Pathog 2005; 1: E30.
111. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: An effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006; 24: 677-688.
112. Harrington LE, Mangan PR,Weaver CT. Expanding the effector CD4 T-cell repertoire: The Th17 lineage. Curr Opin Immunol 2006; 18: 349-356.
113. Lim HW, Lee J, Hillsamer P, Kim CH. Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+regulatory T cells. J Immunol 2008; 180: 122-129.
114. Meyer EH, Wurbel MA, Staton TL, et al. iNKT cells require CCR4 to localize to the airways and to induce airway hyperreactivity. J Immunol 2007; 179: 4661-4671.
115. Sekiya T, Tsunemi Y, Miyamasu M, et al. Variations in the human Th2-specific chemokine TARC gene. Immunogenetics 2003; 54: 742-745.
116. Aujla SJ, Dubin PJ, Kolls JK. Interleukin-17 in pulmonary host defense. Exp Lung Res 2007; 33: 507-518.
117. Aujla SJ, Dubin PJ, Kolls JK. Th17 cells and mucosal host defense. Semin Immunol 2007; 19: 377-382.
118. Dubin PJ, Kolls JK. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 2007; 292: L519-528.
119. McAllister F, Henry A, Kreindler JL, et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: Implications for airway inflammation in cystic fibrosis. J Immunol 2005; 175: 404-412.
120. Aujla SJ, Chan YR, Zheng M, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008; 14: 275-281.